RESPIRATORY SYNCYTIAL VIRUS (RSV)
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS (RSV) explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS (RSV) trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One shot, two viruses? new mRNA vaccine targets RSV and hMPV
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage trial tests an experimental mRNA vaccine called mRNA-1365 in healthy adults aged 60 and older. The vaccine is designed to trigger immunity against two respiratory viruses—RSV and hMPV—which can cause severe illness in older people. Researchers will evaluate the v…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
New mRNA vaccine aims to shield against RSV
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage trial tests an experimental mRNA vaccine called YKYY025 designed to protect against respiratory syncytial virus (RSV). Healthy adults aged 18 and older receive a single injection of either the vaccine or a placebo. Researchers monitor safety, side effects, and im…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE1 • Sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 12, 2026 00:00 UTC
-
Scientists test RSV vaccine to boost immune memory
⭐️ VACCINE ⭐️ Not yet recruitingThis study will test a new RSV vaccine in 60 adults aged 20 and older. Researchers want to understand how the vaccine triggers the immune system to create strong antibodies and memory T cells. The goal is to learn how to make RSV vaccines more effective.
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: NA • Sponsor: MAXVAX Biotechnology Limited Liability Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
New RSV vaccine trial aims to protect women from respiratory virus
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage study tests a new vaccine (MKK900) against respiratory syncytial virus (RSV) in 120 healthy women aged 18 to 49. The main goal is to check if the vaccine is safe and triggers a strong immune response. Participants will receive either the new vaccine or an active …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE1 • Sponsor: MAXVAX Biotechnology Limited Liability Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:00 UTC
-
Pregnancy shot may shield newborns from deadly RSV – major brazil trial launches
⭐️ VACCINE ⭐️ Not yet recruitingThis study will check how well a new RSV vaccine (RSVpreF) works when given to pregnant women in Brazil. Researchers will follow 5,000 infants up to 6 months old who are hospitalized or seen in clinics for respiratory illness. By comparing babies whose mothers got the vaccine to …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Sponsor: Inova Medical • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:09 UTC
-
Massive RSV vaccine study uses real-world data to see if shots prevent severe illness
Disease control Not yet recruitingThis study looks at the real-world effectiveness of the RSV vaccine Abrysvo in adults. Researchers will analyze health records from over 290,000 people to compare those who got the vaccine with those who did not. The goal is to see if the vaccine reduces hospitalizations and othe…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Sponsor: Pfizer • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
One shot to stop RSV: landmark trial for indigenous kids
Prevention Not yet recruitingThis study tests whether a single dose of nirsevimab, an antibody that targets RSV, can prevent respiratory infections in Aboriginal and Torres Strait Islander children aged 6 months. Around 1,000 children will be randomly assigned to receive either the antibody or standard care.…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE4 • Sponsor: Menzies School of Health Research • Aim: Prevention
Last updated Jun 27, 2026 12:31 UTC
-
New RSV shot for babies enters early human trials
Prevention Not yet recruitingThis study tests a new medicine called SIBP-A16 to see if it can safely prevent RSV in infants under 1 year old, including those born early. About 36 babies will receive either the new drug, a placebo, or an existing RSV drug. The main goal is to check for side effects and how th…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Institute Of Biological Products • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC